SCHEMBL25545463

SCHEMBL25545463

CC(C)Cc1sc(N)nc1-c1ccc(OC2CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.41
MYC P01106 1/20 0.38
WDR5 P61964 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP1A2 P05177 1/20 0.36
MAP4K4 O95819 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
CHEK2 O96017 1/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
XBP1 P17861 1/20 0.35
MAPK1 P28482 1/20 0.35
TNK2 Q07912 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25545465 0.86 FBP1 (0.41) FBP1MAPTMEN1KMT2AMAP4K4
SCHEMBL25551235 0.85 ACACB (0.35) MAP4K4CHEK2
SCHEMBL25545439 0.83 MYC (0.51) FBP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL23792635 0.77 SMN1; SMN2 (0.49) FBP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL18391844 0.77 ALDH1A1 (0.69) FBP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL25545495 0.75 TNK2 (0.40) FBP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL30173767 0.74 ALDH1A1 (0.49) FBP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL23782341 0.74 ALDH1A1 (0.49) FBP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL23782509 0.71 ALDH1A1 (0.51) FBP1ALDH1A1SMN1; SMN2GAAMAPT
SCHEMBL25184424 0.70 CD274 (0.54) FBP1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FBP1 735/4885ALDH1A1 4776/4885SMN1; SMN2 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.